

## EMERGING STRATEGIES FOR HEART FAILURE ROUNDTABLE

## **AGENDA**

## **Tuesday, July 19, 2016**

7:00 a.m.	BREAKFAST
7:30 a.m.	Welcome to the Heart House Mary Norine Walsh, MD, FACC, ACC President-Elect
7:40 a.m.	Opening Remarks and Introductions Clyde Yancy, MD, MSc, MACC and James Januzzi, Jr., MD, FACC
8:00 a.m.	Session 1. Accountability in Heart Failure: The Challenges and Complementary Nature of Adherence, Measurement and Evolving Science
	• What does care optimization for heart failure mean?  Larry Allen, MD, MHS, FACC (10 minutes)
	• Co-morbidities in HF: Defining a new unmet need Gregg Fonarow, MD, FACC (10 minutes)
	<ul> <li>How might biomarkers and other strategies help establish adequacy of care?</li> <li>James Januzzi, Jr., MD, FACC (10 minutes)</li> </ul>
	<ul> <li>Interactive table discussion</li> <li>Facilitated by Lee Goldberg, MD, MPH, FACC (60 minutes)</li> </ul>
	<ul> <li>Report back to the full group (30 minutes)</li> </ul>
	<ul> <li>Videotaping of panel discussion         Featuring Larry Allen, MD, MHS, FACC; Gregg Fonarow, MD, FACC; James         Januzzi, Jr., MD, FACC; Ty Gluckman, MD, FACC; Thomas Maddox, MD, MSc,         FACC; Shweta Motiwala, MD (10 minutes)</li> </ul>
10:15 a.m.	BREAK

## 10:30 a.m. Session 2. New Medications, New Choices – Which Guideline Directed Medical Therapy Should Be Used For Optimal Medical Therapy?

- What do the new guidelines say? Clarity or confusion?
   Akshay Desai, MD, MPH, FACC (10 minutes)
- HFrEF: Sacubitril/Valsartan: Why, who, when and how?
   Akshay Desai, MD, MPH, FACC (10 minutes)
- HFrEF: Ivabradine: Why, who, when and how?
   Adrian Hernandez, MD, MHS (10 minutes)
  - Interactive table discussion
     Facilitated by Pamela Peterson, MD, FACC (60 minutes)
  - o Report back to the full group (30 minutes)
  - Videotaping of panel discussion
     Featuring Akshay Desai, MD, MPH, FACC; Adrian Hernandez, MD, MHS; Steven
     Hollenberg, MD, FACC; Herb Patterson, PharmD, FCCP; Shweta Motiwala, MD
     (10 minutes)

12:45 p.m.	LUNCH
1:45 p.m.	Session 3. Prevention of AHA Stage C Heart Failure
	• Stop it before it happens – the prevention of heart failure: the role of biomarkers, imaging and the importance of hypertension Clyde Yancy, MD, MSc, MACC (10 minutes)
	• Diabetes and heart failure: Do we have an answer?  Javed Butler, MD, MBA, MPH, FACC (10 minutes)
	<ul> <li>Cancer &amp; heart failure: Avoiding LV injury Stage A/B patients?</li> <li>Mariell Jessup, MD, FACC (10 minutes)</li> </ul>
	<ul> <li>Interactive table discussion</li> <li>Facilitated by Mary Norine Walsh, MD, FACC (60 minutes)</li> </ul>
	<ul> <li>Report back to the full group (30 mins)</li> </ul>
	<ul> <li>Videotaping of panel discussion         Featuring Clyde Yancy MD, MACC; Javed Butler, MD, MBA, MPH, FACC;         Mariell Jessup, MD, FACC; Leslie Davis, PhD, RN, FAANP; Peter Pang, MD,         MSc, FACC; JoAnn Lindenfeld, MD, FACC (10 minutes)</li> </ul>
4:00 p.m.	BREAK
4:15 p.m.	Recap of the Day and Next Steps
5:00 p.m.	ADJOURN